Actively Recruiting
The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2026-05-14
30
Participants Needed
6
Research Sites
214 weeks
Total Duration
On this page
Sponsors
T
The First Affiliated Hospital with Nanjing Medical University
Lead Sponsor
N
Nanjing Legend Biotech Co.
Collaborating Sponsor
AI-Summary
What this Trial Is About
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product in the Treatment of Relapsed/Refractory B-cell Malignancies.
CONDITIONS
Official Title
The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntary participation with signed informed consent before any study-specific procedures
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- At least one tumor lesion that can be evaluated
- Relapsed or refractory non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) with indication for treatment
- Life expectancy of at least 3 months
- Clinical laboratory values meet screening criteria
- Adequate organ function
You will not qualify if you...
- Insufficient washout period after prior antitumor therapy
- Prior treatment with lentiviral vector-based gene therapies
- Positive for hepatitis B surface antigen, hepatitis B DNA, hepatitis C antibody, hepatitis C RNA, or HIV antibody
- History of severe allergic or hypersensitivity reactions to study drug components or related substances
- Lactating women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
The First Affiliated Hospital of USTC west district
Hefei, Anhui, China, 230000
Actively Recruiting
2
Beijing Gobroad Boren Hospita
Beijing, Beijing Municipality, China, 102206
Actively Recruiting
3
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China, 050000
Actively Recruiting
4
The First Affiliated Hospital of ZHENGZHOU University
Zhengzhou, Henan, China, 450000
Not Yet Recruiting
5
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China, 430000
Actively Recruiting
6
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China, 210029
Actively Recruiting
Research Team
F
FAN Lei
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here